Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06346691
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-05
First Post:
2024-03-28
Brief Title:
Bronchodilator Effect of Oral Doxofylline and Procaterol in Chronic Obstructive Pulmonary Disease
Sponsor:
Thammasat University
Organization:
Thammasat University
Study Overview
Official Title:
Bronchodilator Effect of Oral Doxofylline and Procaterol in Chronic Obstructive Pulmonary Disease A Randomized Crossover Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to determine if doxofylline and procaterol are effective in treating patients with stable chronic obstructive pulmonary disease COPD It will also assess the safety of both drugs
The main questions it aims to answer are
Does doxofylline demonstrate a comparable bronchodilator effect to procaterol in COPD participants
What medical problems do participants experience when taking doxofylline and procaterol
The main questions it aims to answer are
Does doxofylline demonstrate a comparable bronchodilator effect to procaterol in COPD participants
What medical problems do participants experience when taking doxofylline and procaterol
Detailed Description:
This study is a randomized crossover study COPD patients aged 40 years or older with stable disease were included Each patient received 4 weeks of treatment with either doxofylline or procaterol followed by a 2-week washout period and then 4 weeks of treatment with the other drug Respiratory symptoms were assessed by modified Medical Research Council mMRC dyspnea scale and COPD Assessment Test CAT Pulmonary functions were assessed by spirometry with bronchodilator testing and adverse events were recorded Spirometry data including forced expiratory volume in 1 second FEV1 forced vital capacity FVC and forced expiratory flow at 25-75 of FVC FEF25-75 were also collected
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None